OSE Immunotherapeutics SA , today announced that the company has entered into a worldwide license option agreement with Servier , an independent international pharmaceutical company, for the development and commercialization of OSE Immunotherapeutics’ Effi-7, an antagonist of the interleukin-7 receptor. Under the terms of the agreement, OSE Immunotherapeutics grants Servier a license option on the exclusive worldwide rights for the development and commercialization of its product Effi-7.